Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial

Marieke L Duiverman, Johan B Wempe, Gerrie Bladder, Judith M Vonk, Jan G Zijlstra, Huib A M Kerstjens, Peter J Wijkstra, Marieke L Duiverman, Johan B Wempe, Gerrie Bladder, Judith M Vonk, Jan G Zijlstra, Huib A M Kerstjens, Peter J Wijkstra

Abstract

Background: The use of noninvasive intermittent positive pressure ventilation (NIPPV) in chronic obstructive pulmonary disease (COPD) patients with chronic hypercapnic respiratory failure remains controversial as long-term data are almost lacking. The aim was to compare the outcome of 2-year home-based nocturnal NIPPV in addition to rehabilitation (NIPPV + PR) with rehabilitation alone (PR) in COPD patients with chronic hypercapnic respiratory failure.

Methods: Sixty-six patients could be analyzed for the two-year home-based follow-up period. Differences in change between the NIPPV + PR and PR group were assessed by a linear mixed effects model with a random effect on the intercept, and adjustment for baseline values. The primary outcome was health-related quality of life (HRQoL); secondary outcomes were mood state, dyspnea, gas exchange, functional status, pulmonary function, and exacerbation frequency.

Results: Although the addition of NIPPV did not significantly improve the Chronic Respiratory Questionnaire compared to rehabilitation alone (mean difference in change between groups -1.3 points (95% CI: -9.7 to 7.4)), the addition of NIPPV did improve HRQoL assessed with the Maugeri Respiratory Failure questionnaire (-13.4% (-22.7 to -4.2; p = 0.005)), mood state (Hospital Anxiety and Depression scale -4.0 points (-7.8 to 0.0; p = 0.05)), dyspnea (Medical Research Council -0.4 points (-0.8 to -0.0; p = 0.05)), daytime arterial blood gases (PaCO2 -0.4 kPa (-0.8 to -0.2; p = 0.01); PaO2 0.8 kPa (0.0 to 1.5; p = 0.03)), 6-minute walking distance (77.3 m (46.4 to 108.0; p < 0.001)), Groningen Activity and Restriction scale (-3.8 points (-7.4 to -0.4; p = 0.03)), and forced expiratory volume in 1 second (115 ml (19 to 211; p = 0.019)). Exacerbation frequency was not changed.

Conclusions: The addition of NIPPV to pulmonary rehabilitation for 2 years in severe COPD patients with chronic hypercapnic respiratory failure improves HRQoL, mood, dyspnea, gas exchange, exercise tolerance and lung function decline. The benefits increase further with time.

Trial registration: ClinicalTrials.Gov (ID NCT00135538).

Figures

Figure 1
Figure 1
Flow diagram of the study progress. The present article presents the results of the home-based 3-24 month period, shown with a black square around it. QoL: health-related Quality of Life; ABG: arterial blood gases; 6MWD: 6-minute walking distance; LF: lung function measurements.
Figure 2
Figure 2
Maugeri Respiratory Failure scores. MRF scores at the different measurement points in the NIPPV + rehabilitation group (black triangles) and the rehabilitation group (grey blocks). Lower scores signify better quality of life. The change was significantly better in the NIPPV + rehabilitation group (p < 0.02).
Figure 3
Figure 3
Daytime arterial blood gases. Daytime arterial blood gases without additional oxygen at the different measurement points in the NIPPV + rehabilitation group (black triangles) and the rehabilitation group (grey blocks). The change was significantly better in the NIPPV + rehabilitation group (p < 0.02).
Figure 4
Figure 4
6-minute walking distance. 6MWD in meters at the different measurement points in the NIPPV + rehabilitation group (black triangles) and the rehabilitation group (grey blocks). The change was significantly better in the NIPPV + rehabilitation group (p < 0.001).
Figure 5
Figure 5
Forced expiratory volume in 1 second (FEV1). FEV1 in liters (L) at the different measurement points in the NIPPV + rehabilitation group (black triangles) and the rehabilitation group (grey blocks). The change was significantly better in the NIPPV + rehabilitation group (p < 0.02).

References

    1. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010.
    1. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2006. p. CD003793.
    1. Wijkstra PJ, Ten Vergert EM, van Altena R, Otten V, Kraan J, Postma DS, Koëter GH. Long-term benefits of rehabilitation at home on quality of life and exercise tolerance in patients with chronic obstructive pulmonary disease. Thorax. 1995;50:824–828. doi: 10.1136/thx.50.8.824.
    1. Wedzicha JA, Bestall JC, Garrod R, Garnham R, Paul EA, Jones PW. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients stratified with the MRC dyspnoea scale. Eur Respir J. 1998;12:363–369. doi: 10.1183/09031936.98.12020363.
    1. Duiverman ML, Wempe JB, Bladder G, Jansen DF, Kerstjens HA, Zijlstra JG, Wijkstra PJ. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax. 2008;63:1052–1057. doi: 10.1136/thx.2008.099044.
    1. Garrod R, Mikelsons C, Paul EA, Wedzicha JA. Randomized controlled trial of domiciliary non-invasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:1335–1341.
    1. Celli B, Lee H, Criner G, Bermudez M, Rassulo J, Gilmartin M, Miller G, Make B. Controlled trial of external negative pressure ventilation in patients with severe chronic airflow obstruction. Am Rev Respir Dis. 1989;140:1251–1256.
    1. Köhnlein T, Schönheit-Kenn U, Winterkamp S, Welte T, Kenn K. Noninvasive ventilation in pulmonary rehabilitation of COPD patients. Respir Med. 2009;103:1329–1336. doi: 10.1016/j.rmed.2009.03.016.
    1. Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF, Ambrosino N. Rehabilitation and Chronic Care Study Group, Italian Association of Hospital Pulmonologists (AIPO) The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J. 2002;20:529–538. doi: 10.1183/09031936.02.02162001.
    1. Casanova C, Celli BR, Tost L, Soriano E, Abreu J, Velasco V, Santolaria F. Longterm controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest. 2000;118:1582–1590. doi: 10.1378/chest.118.6.1582.
    1. McEvoy RD, Pierce RJ, Hillman D, Esterman A, Ellis EE, Catcheside PG, O'Donoghue FJ, Barnes DJ, Grunstein RR. Australian trial of non-invasive Ventilation in Chronic Airflow Limitation (AVCAL) Study Group. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax. 2009;64:561–566. doi: 10.1136/thx.2008.108274.
    1. Schönhofer B. Non-invasive positive pressure ventilation in patients with stable hypercapnic COPD: light at the end of the tunnel? Thorax. 2010;65:765–767. doi: 10.1136/thx.2010.145276.
    1. Pocock SJ. Clinical Trials: a practical approach. Chichester, England: Johan Wiley; 1983. pp. 84–87.
    1. Vogiatzis I, Nanas S, Roussos C. Interval training as an alternative modality to continuous exercise in patients with COPD. Eur Respir J. 2002;20:12–19. doi: 10.1183/09031936.02.01152001.
    1. Lötters F, van Tol B, Kwakkel G, Gosselink R. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur Respir J. 2002;20:57–66.
    1. Storre JH, Steurer B, Kabitz HJ, Dreher M, Windisch W. Transcutaneous PCO2 monitoring during initiation of noninvasive ventilation. Chest. 2007;132:1810–1816. doi: 10.1378/chest.07-1173.
    1. Hazenberg A, Zijlstra JG, Kerstjens HA, Wijkstra PJ. Validation of a transcutaneous CO(2) monitor in adult patients with chronic respiratory failure. Respiration. 2011;81:242–246. doi: 10.1159/000323074.
    1. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773–778. doi: 10.1136/thx.42.10.773.
    1. Carone M, Bertolotti G, Anchisi F, Zotti AM, Donner CF, Jones PW. Analysis of factors that characterize health impairment in patients with chronic respiratory failure. Eur Respir J. 1999;13:1293–1300. doi: 10.1183/09031936.99.13613019.
    1. Windisch W, Freidel K, Schucher B, Baumann H, Wiebel M, Matthys H, Petermann F. The Severe Respiratory Insufficiency (SRI) Questionnaire: a specific measure of health-related quality of life in patients receiving home mechanical ventilation. J Epidemiol. 2003;56:752–759. doi: 10.1016/S0895-4356(03)00088-X.
    1. Task group on surveillance for respiratory hazards in the occupational setting. Brooks SM (Chairman). Surveillance for respiratory hazards. ATS News. 1982;8:12–16.
    1. Kempen GI, Suurmeijer TP. The development of a hierarchical polychomotomous ADL-IADL scale for noninstitutionalized elders. Gerontologist. 1990;30:497–502. doi: 10.1093/geront/30.4.497.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–415. doi: 10.1016/0197-2456(89)90005-6.
    1. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963–974. doi: 10.2307/2529876.
    1. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497–1505. doi: 10.1001/jama.272.19.1497.
    1. Lappere TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ. Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern. 2009;151:517–527.
    1. Burns GP, Gibson GJ. A novel hypothesis to explain the bronchoconstrictor effect of deep inspiration in asthma. Thorax. 2002;57:116–119. doi: 10.1136/thorax.57.2.116.
    1. Dreher M, Storre JH, Schmoor C, Windisch W. High-intensity versus low-intensity non-invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. Thorax. 2010;65:303–308. doi: 10.1136/thx.2009.124263.
    1. Windisch W, Kostić S, Dreher M, Virchow JC Jr, Sorichter S. Outcome of patients with stable COPD receiving controlled noninvasive positive pressure ventilation aimed at a maximal reduction of Pa(CO2) Chest. 2005;128:657–662. doi: 10.1378/chest.128.2.657.
    1. Elliot MW. Domiciliary non-invasive ventilation in stable COPD? Thorax. 2009;64:553–556. doi: 10.1136/thx.2009.113423.
    1. Brooks D, Krip B, Mangovski-Alzamora S, Goldstein RS. The effect of postrehabilitation programmes among individuals with chronic obstructive pulmonary disease. Eur Respir J. 2002;20:20–29. doi: 10.1183/09031936.02.01852001.
    1. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1995;122:823–832.
    1. Heppner PS, Morgan C, Kaplan RM, Ries AL. Regular walking and long-term maintenance of outcomes after pulmonary rehabilitation. J Cardiopulm Rehabil. 2006;26:44–53. doi: 10.1097/00008483-200601000-00010.
    1. Duiverman ML, Wempe JB, Bladder G, Kerstjens HAM, Wijkstra PJ. Health-related quality of life in COPD patients with chronic respiratory failure. Eur Respir J. 2008;32:379–386. doi: 10.1183/09031936.00163607.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다